American Assets Inc. Makes New $872,000 Investment in Lantheus Holdings, Inc. $LNTH

American Assets Inc. bought a new position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 17,000 shares of the medical equipment provider’s stock, valued at approximately $872,000. Lantheus makes up about 0.3% of American Assets Inc.’s investment portfolio, making the stock its 11th biggest position.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Hantz Financial Services Inc. raised its holdings in shares of Lantheus by 412.5% during the 3rd quarter. Hantz Financial Services Inc. now owns 492 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 396 shares in the last quarter. Elevation Point Wealth Partners LLC bought a new position in Lantheus in the second quarter valued at about $26,000. First Horizon Corp bought a new position in Lantheus in the third quarter valued at about $26,000. Osterweis Capital Management Inc. acquired a new position in Lantheus during the second quarter worth about $36,000. Finally, Pilgrim Partners Asia Pte Ltd bought a new position in shares of Lantheus in the third quarter worth about $59,000. 99.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Mizuho lifted their price target on shares of Lantheus from $60.00 to $72.00 and gave the company an “outperform” rating in a report on Wednesday, December 17th. Truist Financial lifted their price target on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a report on Thursday, December 18th. Finally, Weiss Ratings upgraded shares of Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, January 6th. Five analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $78.00.

Lantheus Price Performance

Lantheus stock opened at $64.89 on Friday. Lantheus Holdings, Inc. has a 52 week low of $47.25 and a 52 week high of $111.29. The company’s 50 day moving average price is $65.59 and its two-hundred day moving average price is $59.64. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The stock has a market cap of $4.30 billion, a P/E ratio of 27.26 and a beta of -0.08.

Lantheus (NASDAQ:LNTH) last released its earnings results on Thursday, November 6th. The medical equipment provider reported $1.27 earnings per share (EPS) for the quarter, meeting the consensus estimate of $1.27. The company had revenue of $384.01 million during the quarter, compared to analyst estimates of $363.42 million. Lantheus had a return on equity of 30.88% and a net margin of 10.99%.Lantheus’s quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.70 earnings per share. On average, equities analysts predict that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.